RemeGenix Inc.
This article was originally published in Start Up
Executive Summary
Recently launched RemeGenix aims to move quickly into the clinic with multifunctional drugs that address the biological mechanisms at the heart of neurodegeneration, not merely treat the symptoms. Its candidates for TBI are cyclic dipeptides structurally related to the major metabolic product of TRH (thyrotropin-releasing hormone). The drugs down-regulate several major injury pathways while up-regulating endogenous neuroprotective pathways.